Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
Palisade Bio reported Q1 financial results with a net loss of $0.05 per share, driven by a significant ramp in R&D spending to $6.4 million as PALI-2108 advances toward Phase 2 trials. The company ended the quarter with $132.6 million in cash, providing a runway that management expects to fund operations through key efficacy readouts in 2028.
Key figures
- Net loss
- 9600000
- Ga expenses
- 4400000
- Rd expenses
- 6400000
- Cash position
- 132600000
- Stock based comp
- 4297000
- Phase2 cd initiation
- Q1 2027
- Phase2 uc initiation
- Q3 2026
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.